Valneva SE (VALN) Accumulated Expenses (2020 - 2025)
Valneva SE's (VALN) quarterly Accumulated Expenses came in at $14.7 million in Q4 2025, up 5.07% year-on-year from $14.0 million in Q4 2024, and up 5.07% quarter-over-quarter from $14.0 million in Q4 2024.
Valneva SE (VALN) Accumulated Expenses (2020 - 2025) Analysis & Trends
Valneva SE has disclosed Accumulated Expenses across 6 years of filings, most recently posting $14.7 million for Q4 2025.
- Accumulated Expenses for Q4 2025 came in at $14.7 million, up 5.07% year-over-year; the trailing twelve-month figure through Dec 2025 was $14.7 million (up 5.07% YoY), and the FY2025 annual result was $14.7 million, up 5.07% from the prior year.
- Accumulated Expenses came in at $14.7 million for Q4 2025 at Valneva SE, up from $14.0 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $14.7 million in Q4 2025 to a low of $10.9 million in Q2 2024.
- The 5-year median for Accumulated Expenses is $11.6 million (2021), against an average of $12.3 million.
- Across the five-year window, Accumulated Expenses fell 4.84% in 2022 and grew 20.37% in 2024, its largest moves.
- Valneva SE's Accumulated Expenses stood at $11.6 million in 2021, then retreated by 4.84% to $11.0 million in 2022, then gained by 5.82% to $11.6 million in 2023, then gained by 20.37% to $14.0 million in 2024, then climbed by 5.07% to $14.7 million in 2025.
- The last three Accumulated Expenses figures came in at $14.7 million (Q4 2025), $14.0 million (Q4 2024), and $10.9 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.72 Mn |
| Dec 31, 2024 | 14.01 Mn |
| Jun 30, 2024 | 10.93 Mn |
| Dec 31, 2023 | 11.64 Mn |
| Dec 31, 2022 | 11.00 Mn |
| Dec 31, 2021 | 11.56 Mn |
| Dec 31, 2020 | 9.90 Mn |